Publications by authors named "S St Cyr"
Article Synopsis
- The study aimed to assess long-term infection rates in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) treated with the medication dupilumab.
- It analyzed data from an ongoing open-label extension (OLE) study, showing that long-term dupilumab treatment resulted in lower infection rates compared to previous shorter trials.
- The findings indicate that dupilumab treatment is associated with a reduced frequency of infections and is considered safe for young children with AD.
Article Synopsis
- In end-stage diseases, having a limited number of donors led to the creation of various pre-transplant psychosocial assessment tools to evaluate candidates.
- A literature review identified thirteen studies focusing on four assessment scales, with TERS and MBHI showing the most positive correlations with transplant outcomes.
- The review suggests that while these psychosocial scales can help predict health behaviors and outcomes, there's a need for better clinical trials and multidisciplinary approaches for effective candidate evaluation.
Alzheimer's disease (AD) and osteoporosis often coexist in the elderly. Although observational studies suggest an association between these two diseases, the pathophysiologic link between AD and skeletal health has been poorly defined. We examined the skeletal phenotype of 5xFAD mice, an AD model with accelerated neuron-specific amyloid-β accumulation causing full-blown AD phenotype by the age of 8 months.
View Article and Find Full Text PDFFibroblast growth factor 23 (FGF23) production has recently been shown to increase downstream of Gαq/11-PKC signaling in osteocytes. Inactivating mutations in the gene encoding Gα11 (GNA11) cause familial hypocalciuric hypercalcemia (FHH) due to impaired calcium-sensing receptor signaling. We explored the effect of Gα11 deficiency on FGF23 production in mice with heterozygous (Gna11+/-) or homozygous (Gna11-/-) ablation of Gna11.
View Article and Find Full Text PDFBackground And Objective: Current regulatory labeling recommends avoiding live vaccine use in dupilumab-treated patients. Clinical data are not available to support more specific guidance for live or live attenuated vaccines administration in dupilumab-treated patients.
Methods: Children (6 months-5 years old) with moderate-to-severe atopic dermatitis (AD) enrolled in a phase 2/3 clinical trial of dupilumab (LIBERTY AD PRESCHOOL Part A/B; NCT03346434) and subsequently participated in the LIBERTY AD PED-OLE (NCT02612454).